
Study Period | 2019 - 2030 |
Market Size (2025) | USD 0.9 Billion |
Market Size (2030) | USD 1.21 Billion |
CAGR (2025 - 2030) | 5.94 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players![]() *Disclaimer: Major Players sorted in no particular order |
Global Amyotrophic Lateral Sclerosis Treatment Market Analysis
The Global Amyotrophic Lateral Sclerosis Treatment Market size is estimated at USD 0.9 billion in 2025, and is expected to reach USD 1.21 billion by 2030, at a CAGR of 5.94% during the forecast period (2025-2030).
In recent years, the amyotrophic lateral sclerosis (ALS) treatment market has been driven by increasing awareness of advancements in neurobiology and growing investments in the development of innovative therapies. Furthermore, progress in stem cell and gene therapies is creating significant opportunities for future treatment solutions, thereby accelerating market growth.
Several initiatives have been taken by the government authoritative bodies to fast-track the development of novel drugs and treatments which is projected to drive the market growth. For instance, in 2023, the National Institute of Neurological Disorders and Stroke (NINDS) outlined strategic priorities for ALS research, aiming to speed up the creation of effective interventions for ALS diagnosis, treatment, management, prevention, and potential cures. These priorities were shaped with insights from scientists, clinicians, advocates, individuals impacted by ALS, and the broader public. Additionally, under the "Accelerating Access to Critical Therapies for ALS Act," NINDS is funding research to provide investigational new drugs to ALS patients not qualifying for clinical trials. Such proactive government measures are set to significantly boost market growth for ALS treatments.
Moreover, increased investments in research and the approval of new drugs, including Qalsody, Radicava, Rilutek, Tiglutik, Exservan, and Nuedexta, have played a pivotal role in propelling market growth. For example, in April 2023, Biogen Inc. received the U.S. Food and Drug Administration (FDA) approval for its QALSODY (tofersen) 100 mg/15mL injection. This drug is specifically designed for treating amyotrophic lateral sclerosis (ALS) in adults with a mutation in the superoxide dismutase 1 (SOD1) gene. These groundbreaking product launches not only enhance patient outcomes but also broaden treatment options, further driving market expansion.
Furthermore, increased awareness of Amyotrophic Lateral Sclerosis (ALS) among healthcare providers and the general public leads to earlier and more accurate diagnoses, enabling timely intervention and treatment. This heightened awareness and improved diagnostics result in a larger patient population seeking specialized therapies, thereby driving growth in the ALS treatment market. For example, in June 2024, the ALS Association chose InnoVision Marketing Group as its agency to create media campaigns to raise awareness of amyotrophic lateral sclerosis (ALS). The goal is to raise awareness and highlight the need for community support for those living with ALS. As awareness grows among patients and healthcare professionals about ALS and available treatments, diagnosis rates are rising, driving demand for ALS drugs. This increased awareness is likely to lead to earlier diagnosis and treatment, resulting in better patient outcomes and increased market growth.
Therefore, owing to the aforementioned factors such as the growing government initiatives, approvals and launches by market players, and increased awareness and diagnosis, the studied market is anticipated to witness growth over the analysis period. However, the high cost of treatment is estimated to restrain market growth.
Global Amyotrophic Lateral Sclerosis Treatment Market Trends
The Medication Segment Is Expected To Witness Significant Growth Over The Forecast Period.
Medications in amyotrophic lateral sclerosis treatment are expected to witness healthy growth as they help relieve symptoms, panic attacks, pain, and depression.
The rising clinical trial developments for new drug discovery for ALS treatment are projected to boost the growth of the market segment. For instance, in October 2024, Avextra AG launched a Phase 2 trial in Italy to test a cannabis-based oral medication for the management of symptoms in people with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The clinical studies have demonstrated that medical cannabis can help to manage pain, sleep issues, appetite loss, stiff muscles, and depression in ALS. Avextra aims to develop safe and effective cannabis-based medicines for patients in whom conventional therapies have failed to provide adequate symptom relief.
Additionally, in February 2024, the AI-discovered ALS drug, FB1006, completed patient enrollment in the investigator-initiated clinical trial (IIT) for the treatment of ALS. The program was conducted at the Third Hospital of Peking University and is expected to complete the one-year clinical observation in February 2025. Successful clinical trials can lead to regulatory approvals, which in turn brings new medications to market, offering hope to patients and expanding treatment options.
Furthermore, the growing number of product approvals is anticipated to boost the segmental growth over the forecast period. For instance, in September 2024, Eisai Co., Ltd. obtained manufacturing and marketing authorization for "Rozebalamin for Injection 25 mg" (mecobalamin), a treatment for amyotrophic lateral sclerosis (ALS) in Japan. This approval is aimed at slowing the progression of functional impairment in ALS patients. Such regulatory nods not only pave the way for new revenue avenues for pharmaceutical firms but also broaden the treatment landscape for ALS, fueling growth in the sector.
Moreover, the initiatives by the government to advance the treatment of rare neurological diseases including ALS is also contributing to the segment’s growth. For instance, in September 2023, the Food & Drugs Administration (FDA) introduced a pilot program aimed at accelerating the development of therapies for rare diseases, including Amyotrophic Lateral Sclerosis (ALS). By streamlining regulations and fostering innovation, this initiative seeks to encourage pharmaceutical companies to increase their investment in ALS treatment research. As a result, the program is expected to expedite the launch of new therapies, driving growth in the ALS treatment market.
Therefore, owing to the aforesaid factors, the segment is expected to register a significant growth rate during the forecast period.

North America is Expected is Expected to Dominate Amyotrophic Lateral Sclerosis Market Over the Forecast Period
North America is expected to dominate the market owing to factors such as the rising incidence of rare neurological diseases, high research and development (R&D) spending, product launches, and approvals along with the high concentration of market players in the region.
Moreover, favorable reimbursement policies facilitate innovation and patient access to essential drugs which in turn led to drive the market growth. For instance, in December 2023, Mitsubishi Tanabe Pharma Canada (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), stated that RADICAVA Oral Suspension (edaravone), a treatment for amyotrophic lateral sclerosis (ALS), has been approved for reimbursement by Veterans Affairs Canada (VAC) as a standard benefit and by Indigenous Services Canada under the Non-Insured Health Benefits (NIHB) Program with limited use. ALS is a rapidly progressive neurodegenerative disease. Additionally, most private insurance plans in Canada are estimated to provide coverage for RADICAVA Oral Suspension. These reimbursement initiatives improve patient access to high-cost therapies, thereby supporting market expansion.
Additionally, the advancements in treatment and increasing product approvals by key players are also contributing to market growth in the region. For instance, in November 2024, the FDA granted Orphan Drug Designation to RAG-21 (Ractigen Therapeutics) for the treatment of Amyotrophic Lateral Sclerosis (ALS), recognizing its potential to address the unmet medical needs of patients with this condition. This designation encourages the development and commercialization of RAG-21, potentially accelerating its availability to those affected by ALS. Such initiaves encourages investment and research, facilitating the development of this promising therapy. This designation not only boosts confidence among stakeholders but also stimulates market growth as it signals potential new treatment options for patients suffering from ALS.
Furthermore, increasing collaborations with stem cell therapy institutes in Mexico enhance patient access to advanced treatments, making innovative therapies more widely available for amyotrophic lateral sclerosis (ALS). This accessibility boosts market growth as more patients seek effective treatment options, driving demand in the ALS treatment market.. For instance, in March 2024, Medical Tourism Corporation, a U.S.-based international medical travel company, partnered with GIOSTAR (Global Institute of Stem Cell Therapy and Research) to improve access to stem cell treatments in Mexico. This collaboration, leveraging the potential of stem cells to slow ALS progression, is expected to expand treatment options and drive market growth during the forecast period.
In summary, favorable reimbursement policies, the growing number of collaborations, and product approvals are likely to increase the demand for amyotrophic lateral sclerosis treatment in North America and drive the market's growth during the forecast period.

Global Amyotrophic Lateral Sclerosis Treatment Industry Overview
The amyotrophic lateral sclerosis treatment market is slightly fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some companies are Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc., AB Science, Ionis Pharmaceuticals, Biohaven Pharmaceutical, Biogen, CRISPR Therapeutics, Boehringer Ingelheim International GmbH and ANNEXON, INC.
Global Amyotrophic Lateral Sclerosis Treatment Market Leaders
-
Mitsubishi Tanabe Pharma Corporation
-
CORESTEM, Inc
-
BrainStorm Cell Limited
-
Amylyx Pharmaceuticals Inc.
-
Biogen
- *Disclaimer: Major Players sorted in no particular order

Global Amyotrophic Lateral Sclerosis Treatment Market News
- May 2024: NeuroSense Therapeutics, a company developing novel treatments for severe neurodegenerative diseases partnered with Boston-based company PhaseV, a pioneer in causal machine learning (ML) for clinical trial analysis and optimization, with respect to the planned Phase 3 trial of PrimeC as a treatment for amyotrophic lateral sclerosis (ALS). The collaboration aims to develop the Phase III trial protocol for NeuroSense’s ALS therapy PrimeC (celecoxib and ciprofloxacin). The company plans to use the analysis to inform trial design and patient enrolment, as well as ensure cost-effectiveness.
- May 2024: Biogen received approval from the European Commission (EC) for its QALSODY (tofersen) medication for the treatment of adults with amyotrophic lateral sclerosis (ALS). QALSODY is the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).
Global Amyotrophic Lateral Sclerosis Treatment Industry Segmentation
As per the scope of the report, amyotrophic lateral sclerosis (ALS) is a neurological disorder and fatal disease that affects nerve cells in the neuron and spinal control which controls voluntary muscle movement in the human body. This disorder affects neurons which results in the blockage of messages between muscles and the brain. The amyotrophic lateral sclerosis treatment market is segmented by treatment type, end-user, and geography. By treatment type, the market is segmented into medication, stem cell therapy, and other treatment types. The others segment is further bifurcated into respiratory therapy and chemotherapy. By end-user the market is segmented into hospitals, diagnostic centers, and other end-users. The others segment is further bifurcated into research and academic institutes and homecare settings. The report also covers the market size and forecasts for the amyotrophic lateral sclerosis treatment market in 17 countries across major regions. For each segment, the market sizing and forecasts have been done on the basis of value (USD).
By Treatment Type | Medication | ||
Stem Cell Therapy | |||
Other Treatment Types | |||
By End-user | Hospital | ||
Diagnostic Centers | |||
Other End-users | |||
Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Global Amyotrophic Lateral Sclerosis Treatment Market Research FAQs
How big is the Global Amyotrophic Lateral Sclerosis Treatment Market?
The Global Amyotrophic Lateral Sclerosis Treatment Market size is expected to reach USD 0.9 billion in 2025 and grow at a CAGR of 5.94% to reach USD 1.21 billion by 2030.
What is the current Global Amyotrophic Lateral Sclerosis Treatment Market size?
In 2025, the Global Amyotrophic Lateral Sclerosis Treatment Market size is expected to reach USD 0.9 billion.
Who are the key players in Global Amyotrophic Lateral Sclerosis Treatment Market?
Mitsubishi Tanabe Pharma Corporation, CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc. and Biogen are the major companies operating in the Global Amyotrophic Lateral Sclerosis Treatment Market.
Which is the fastest growing region in Global Amyotrophic Lateral Sclerosis Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global Amyotrophic Lateral Sclerosis Treatment Market?
In 2025, the North America accounts for the largest market share in Global Amyotrophic Lateral Sclerosis Treatment Market.
What years does this Global Amyotrophic Lateral Sclerosis Treatment Market cover, and what was the market size in 2024?
In 2024, the Global Amyotrophic Lateral Sclerosis Treatment Market size was estimated at USD 0.85 billion. The report covers the Global Amyotrophic Lateral Sclerosis Treatment Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Amyotrophic Lateral Sclerosis Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Global Amyotrophic Lateral Sclerosis Treatment Industry Report
The report on the Amyotrophic Lateral Sclerosis (ALS) market provides an in-depth industry analysis, focusing on various treatment types such as medication and others. The market is segmented by distribution channels including hospital pharmacies, retail pharmacies, and others, and covers geographical regions like North America, Europe, Asia-Pacific, Middle East and Africa, and South America.
The industry report highlights the market trends and market growth, offering a detailed market forecast and market overview. It also includes an industry outlook and industry trends, presenting valuable market data and industry statistics. The report example and report PDF provide a comprehensive review of market segmentation and market value.
Furthermore, the industry research delves into market predictions and market review, identifying market leaders and market outlook. The report also features insights into industry sales and industry size, supported by industry information and market analysis. The report underscores the importance of market research and industry reports, offering a thorough industry overview and market forecast.
In summary, the ALS market report is an essential resource for understanding the industry's growth rate, market leaders, and market trends. It provides a clear picture of market segmentation and market value, supported by detailed industry analysis and market data. The report is an invaluable tool for research companies seeking to gain a deeper understanding of the ALS market, offering a comprehensive market review and industry outlook.